France· FR:65647882
KYMRIAH 1,2 x 1 000 000 - 6 x 100 000 000 cellules, dispersion pour perfusion
A medicinal product containing tisagenlecleucel, registered in France by NOVARTIS EUROPHARM (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TISAGENLECLEUCEL
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip133400955057819poche(s) EVA : éthylène vinyl acétate copolymère suremballée(s)/surpochée(s) avec matériel(s) de perfusion - maximum de 50 ml en fonction du patient - 1 ou plusieurs poches
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tisagenlecleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKYMRIAHNovartis Pharmaceuticals Corporation
- CanadaKYMRIAHNOVARTIS PHARMACEUTICALS CANADA INC
- SwitzerlandKymriah, Zellsuspension zur InfusionNovartis Pharma Schweiz AG
- CzechiaKYMRIAHNovartis Europharm Limited, Dublin
- SpainKYMRIAH 1,2 x 10e6 - 6,0 x 10e8 celulas dispersion para perfusionNovartis Europharm Limited
- FinlandKymriahNovartis Europharm Limited
- BelgiumKymriah 1,2 x 10*6 – 6 x 10*8 cellsNovartis Europharm
- United KingdomKymriah 1.2million-600million cells dispersion for infusion bagsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kymriah
- Liechtenstein · Kymriah
- Norway · Kymriah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef1579c2-815d-4f27-bc2d-11fab6e31c0d GET /v1/drugs/ef1579c2-815d-4f27-bc2d-11fab6e31c0d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65647882",
"date_amm": "2018-08-23",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1297",
"substance": "TISAGENLECLEUCEL",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "dispersion pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about tisagenlecleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.